spacer
home > epc > autumn 2008 > hit the mark
PUBLICATIONS
European Pharmaceutical Contractor

Hit the Mark

Increasing pressure is being placed on the pharmaceutical industry to limit the costs and time associated with delivering a drug to the market. First-in-human and other early phase studies are a critical step in the complex process. Normally limited to objectives based around pharmacokinetics, safety and tolerability, early phase studies provide an underutilised opportunity to obtain valuable pharmacodynamic data regarding a drug’s mechanism of action, pharmacological activity and potential dosing regimens. Carefully chosen biomarkers are able to be easily incorporated into early phase drug studies and provide guidance for important decisions concerning a drug’s future.

Analyses show that the largest part of the development costs are spent on failures, particularly in the latter part of the process because of the high costs of large-scale clinical trials (1,2). Consequently, there is much pressure on the drug development process to ‘kill failures early’ by showing that the compound does not have the characteristics of a proper drug – or vice versa – and preferably to show that it does (3). Thus, drug development has become a much more continuous process than is suggested by the ‘classic’ separation into distinct phases. In fact, modern ICH guidelines, as implemented by the regulatory authorities, stipulate the intelligent use of pharmacodynamic drug effect measurements during all stages of development (4-6).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Joop van Gerven is Director of CNS Studies at CHDR. Joop studied English and Medicine at Utrecht University. After obtaining his MD in 1984, he worked in the Department of Internal Medicine of Leiden University Medical Center (LUMC). In 1990 he completed a PhD thesis on aldose reductase inhibitor treatment in diabetes mellitus. He was trained as a Neurologist in Dijkzigt University Hospital in Rotterdam from 1988 to 1994. During that period, he was also a consultant for Wyeth on diabetic complications. Since 1994 he has been responsible for CNS research at CHDR in Leiden, and is responsible for consultancy and research on central nervous system drugs and methods. He is also active clinically as a Consultant Neurologist at LUMC. In 2004 he was appointed Professor of Clinical Psychoneuropharmacology at Leiden University.

Justin Hay is Senior Clinical Scientist, CNS Studies at CHDR. Justin completed his BSc (Biomed Science) with majors in Pharmacology, Microbiology & Immunology (2001) and graduated with First Class Honours (2002). In 2007 he was conferred his PhD in Pharmacology from the University of Adelaide, Australia. His thesis investigated the pain sensitivity of chronic opioid users. Since March 2007, Justin has held his current position, where he is investigating how pain tests can be used as a screening tool in early drug development.

spacer
Professor Joop van Gerven
spacer
spacer
spacer
Justin Hay
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement